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Ask any clinician . . . there isn’t a soul who would disagree. Quality
in health care is important. It would also be difficult to find many who
would disagree that there is much room for improvement in terms of
cancer care quality. The Institute of Medicine’s ‘‘Ensuring Quality
Cancer Care’’ highlighted a dearth of information on the quality of
cancer care and recommended the development of better measures
of the quality of cancer care for use by consumers, providers, and
payers [1]. In response to this report, many healthcare stakeholders
have worked to develop clinical care guidelines based on evidence-
based medicine. However, the question remains: Will widespread
implementation of these guidelines assure better care for cancer
patients?
Recent efforts have focused on the development of quality indica-
tors, which measure processes of care. Quality indicators can be used
as proxies to assess the quality of care being provided to patients.
Findings of variations across providers may represent areas for
improvement. Ideally, problems can be flagged and addressed since
quality indicators help care providers better understand and improve
performance. Physicians and hospitals would use the measurement-
feedback loop to help identify areas for improvement in attempts to
continually improve performance.
Surgeons may be familiar with quality indictors developed by the
Surgical Care Improvement Project (SCIP), which include consensus
standards for hospital care which are specific to perioperative processes
of care. The National Surgical Quality Improvement Program (NSQIP)
has also developed surgery specific measures, evaluating a multitude of
patients’ pre-operative risk factors and post-operative outcomes. SCIP
measures include the appropriate administration of antibiotics and use
of venous thromboembolism prophylaxis in the perioperative period.
The Centers for Medicare and Medicaid Services (CMS) has been
paying hospitals for reporting compliance with certain SCIP quality
measures. In addition to giving hospitals a financial incentive to report
the quality of their services, this hospital reporting program provides
feedback to hospitals and consumers (patients).
Specific cancer care measures have been developed by the
American Society of Clinical Oncology (ASCO) through the Quality
Oncology Performance Initiative (QOPI). QOPI employs a mechanism
for improving cancer care through measurement, feedback and improve-
ment tools for medical oncology practices on a voluntary basis. Practic-
ing oncologists and quality experts developed over 70 quality measures
which were derived from clinical guidelines or published standards.
While QOPI has focused on outpatient practices, both ASCO and the
National Comprehensive Cancer Network (NCCN) have developed
immensely popular clinical care guidelines. Not only have clinicians
relied on these guidelines, CMS has used them as a basis for the
Medicare Quality in Cancer Care Demonstration Project (2006), which
reimbursed physicians for reporting on evidence-based practices.
In 2007, leading cancer organizations such as ASCO, the NCCN,
and the American College of Surgeons Commission on Cancer (ACS-
CoC), jointly developed five quality measures for breast and colon
cancer (Table I). Development of the measures was based on evidence
from a host of patient-level studies supporting improved patient
outcomes if said measures were met. Recognizing that cancer
treatment is an interdisciplinary practice, these quality measures were
meant to be applied and measured at the hospital level. Endorsed by the
National Quality Forum (NQF), these represented the first set of
nationally recognized hospital-based performance measures specific to
the quality of breast and colorectal cancer care.
In general, quality indicators have been popular, and they have been
heralded as a means to help physicians and hospitals assure quality
care. CMS has already paid hospitals and physicians for reporting
results. Not surprising, there is also increasing interest on the part of
third-party payers to incorporate adherence to quality indicators into
their pay-for-performance initiatives. However, there has been some
controversy as to the effectiveness of these measures, since adherence
to them at the hospital level may not necessarily be associated with
improved patient outcomes. For example, the number of lymph nodes
that hospitals examine following colectomy for colon cancer is not
associated with staging, use of adjuvant chemotherapy, or patient
survival even though examining more than 12 nodes seems to portend a
better prognosis for any given patient [2].
Learning what factors affect hospital/physician performance and
patient outcomes is important. What may be more important is how
TABLE I. NQF-Endorsed Quality Measures Developed by ASCO, NCCN,
and ACS-CoC
1. Radiation therapy is administered within 1 year (365 days) of diagnosis for
women under age 70 receiving breast conserving surgery for breast cancer
2. Combination chemotherapy is considered or administered within 4 months
(120 days) of diagnosis for women under 70 with AJCC T1c, or Stage II or
III hormone receptor negative breast cancer
3. Tamoxifen or third generation aromatase inhibitor is considered or
administered within 1 year (365 days) of diagnosis for women with AJCC
T1c or Stage II or III hormone receptor positive breast cancer
4. Adjuvant chemotherapy is considered or administered within 4 months
(120 days) of diagnosis for patients under the age of 80 with AJCC Stage
III (lymph node positive) colon cancer
5. At least 12 regional lymph nodes are removed and pathologically examined
for resected colon cancer
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those things are related. The current state of quality indicators in
surgical oncology represents well-intentioned efforts. However,
implementation and enforcement of quality measures require a
commitment of resources. If policy moves ahead of science, there is
valid concern that efforts may actually detract from other things that
might be more effective in improving quality of care. Effective quality
indicators must be measurable, actionable, and shown to be associated
with optimal outcomes.
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